CERS
Cerus CorporationNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$518.96M
P/E Ratio
—
EPS
$-0.05
Beta
1.77
52W High
$3.15
52W Low
$1.15
50-Day MA
$2.36
200-Day MA
$1.98
Dividend Yield
—
Profit Margin
-4.41%
Forward P/E
—
PEG Ratio
0.00
About Cerus Corporation
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Fundamentals
| Revenue (TTM) | $216.56M |
| Gross Profit (TTM) | $114.76M |
| EBITDA | $-1.62M |
| Operating Margin | -0.66% |
| Return on Equity | -15.40% |
| Return on Assets | -0.93% |
| Revenue/Share (TTM) | $1.13 |
| Book Value | $0.34 |
| Price-to-Book | 7.65 |
| Price-to-Sales (TTM) | 2.40 |
| EV/Revenue | 2.465 |
| EV/EBITDA | 1123.97 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 24.10% |
| Shares Outstanding | $200.37M |
| Float | $181.92M |
| % Insiders | 3.41% |
| % Institutions | 74.68% |
Historical Volatility
HV 10-Day
52.08%
HV 20-Day
67.63%
HV 30-Day
103.71%
HV 60-Day
80.25%
HV Rank
96.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.67 target)
3
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026